TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of papulopustular rosacea~* Free of any clinically significant disease, which could interfere with the study~* Male or female subject aged ≥ 18 years~* Willingness of subject to follow all study procedures~* Signed written informed consent before any study-related activities are carried out~Exclusion Criteria:~* Subjects who are known to be non-responders to azelaic acid~* Presence of dermatoses that might interfere with rosacea diagnosis~* Ocular rosacea; phymatous rosacea; subjects with plaque-type rosacea lesions, papulopustular rosacea that requires systemic treatment~* Topical use of any prescription or non-prescription medication to treat rosacea within 6 weeks prior to randomization and throughout the study~* Systemic use of any prescription or non-prescription medication to treat rosacea (Retinoids within 6 months, Tetracycline within 2 months, Corticosteroids, erythromycin, azithromycin, and/or metronidazole within 4 weeks) prior to randomization and throughout the study~* Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to randomization~* Known hypersensitivity to any ingredients of the investigational product formulation~* Participation in another clinical research in parallel or within the last 4 weeks before randomization in this study~* Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azelaic acid foam, 15% (BAY39-6251) (Type: EXPERIMENTAL): 0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
- Vehicle foam (Type: PLACEBO_COMPARATOR): 0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Drug naive~* Hemoglobin A1c (HbA1c) ≥6.0% and ≤8.0%~* Fasting C-peptide ≥1.0 ng/mL~* Body mass index ≤40 kg/m²~Exclusion Criteria:~* Recent cardiac or cerebrovascular event~* Elevated serum creatinine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (A) (Type: EXPERIMENTAL): Metformin 500-1500 mg (open-label, as needed for rescue in LT)
- Placebo (ST) / Metformin (LT) (B) (Type: PLACEBO_COMPARATOR): Metformin 500-1500 mg (open-label, as needed for rescue in LT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable angina pectoris of class I-III according to the Canadian Cardiovascular Society (CCS) classification and a history of myocardial infarction no earlier (not less) than 3 months before inclusion in the study.~HTN (including resistant\* hypertension)~* Signed informed consent to participate in the study.~* Bisoprolol/ perindopril SPC prescription\*\* within 3 month period before Index date~Exclusion Criteria:~* Hypersensitivity to bisoprolol, perindopril, excipients of the medicine, or other ACE inhibitors.~* Any contraindication for bisoprolol/perindopril's SPC according to the instruction for medical use~* CAD, angina pectoris of functional class IV according to the CCS classification (Appendix 1).~* Chronic heart failure of class III-IV according to the New York Heart Association (NYHA) functional classification of heart failure (Appendix 3).~* Cerebrovascular diseases (ischemic, haemorrhagic stroke, or transient ischemic attack) within the past 6 months prior to inclusion in the study.~* A history of revascularization procedure within 3 months prior to inclusion in the study.~* Hypertrophic obstructive cardiomyopathy.~* Office BP ≥ 180/110 mm Hg on treatment~* Type 1 diabetes mellitus and decompensated type 2 diabetes mellitus.~* Bradycardia with a heart rate of less than 60 beats per minute.~* Atrioventricular block (II-III degree), sinoatrial block, or sick sinus syndrome.~* Severe bronchial asthma or severe chronic obstructive pulmonary disease.~* Arterial hypotension (BP less than 100/70 mm Hg).~* Pregnancy, breastfeeding.~* Secondary hypertension.~* Severe decompensated diseases of organs and systems requiring continuous treatment.~* Current participation in another clinical trial and within 30 days prior to signing informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of neuroendocrine tumor of the duodenum/pancreas by histology or bone scan~* Functional or nonfunctional tumor~  * Tumor meets ≥ 1 of the following criteria:~    * Hepatic or extrahepatic metastases~   * Progressive locally advanced tumor (primary or adenopathies)~* Unresectable disease~* Tumor differentiated and meets the following criteria:~  * Ki 67 ≤ 15%~ * Less than 10 mitoses per 10 large fields~* Measurable or evaluable disease~  * Target lesions must meet 1 of the following criteria within the past 6 months:~    * Increase of 20% in the longest diameter~   * New metastases detected~ * Minimum size of lesions must be 1 of the following:~    * More than 15 mm for metastases~   * More than 50 mm for primary tumor or local lymph nodes~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Creatinine ≤ 1.5 mg/dL~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.8 mg/dL~* No coronary insufficiency or symptomatic cardiac disease~* No intestinal obstruction, enteropathy, or uncontrolled chronic diarrhea~* No Gilbert's disease~* No psychological, social, familial, or geographic condition that would preclude study treatment~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 6 months after completion of study therapy~* No other condition that would preclude study therapy~PRIOR CONCURRENT THERAPY:~* No prior adjuvant radiotherapy~* At least 3 months since prior interferon~* Prior somatostatin analogs or antisecretories allowed~* No other prior treatment for this cancer~* No concurrent radiotherapy to the target lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FOLFIRI (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Methylprednisolone After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective total knee arthroplasty~* Able to speak and understand danish~* Able to give informed consent~Exclusion Criteria:~* Alcohol or medical abuse~* Allergies to local anesthetics or methylprednisolone~* Age \< 18 years~* Daily use of opioids or glucocorticoids~* Pregnancy or breastfeeding (fertile women)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: ACTIVE_COMPARATOR): Methylprednisolone 125 mg iv pre-operatively
- Saline (Type: PLACEBO_COMPARATOR): Saline iv pre-operatively in equivalent volume (placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Vaccinations in Immunocompromised Persons

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Indication for hepatitis A and/or tetanus vaccination according to Swiss Federal Office of Public Health recommendations~* Male and female rheumatic patients with rheumatoid arthritis or axial spondyloarthritis (ankylosing spondylitis, axial psoriatic arthritis, axial undifferentiated spondyloarthritis, enteropahtic arthritis) or peripheral psoriatic arthritis or vasculitis (Behçet's disease or ANCA-associated vasculitis) or male and female healthy participants ≥ 18 years~* Signed Informed Consent after being informed~Exclusion Criteria:~* Known hypersensitivity to a vaccine ingredient~* Estimated patient survival below 1 year~* Active malignant or active infectious disease~* Drug/alcohol abuse~* Insufficient understanding of local language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy controls (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
- Patients with rheumatoid arthritis (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
- Patients with axial spondylarthritis (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
- Patients with vasculitis (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with one of the following documented mastocytosis as per WHO classification: Smouldering Systemic Mastocytosis, Severe Indolent Mastocytosis~2. Patient with documented mastocytosis and evaluable disease based upon histological criteria: typical infiltrates of mast cells in a multifocal or diffuse pattern in skin and/or bone marrow biopsy~3. Patient with documented treatment failure of his/her handicap(s) with at least one of the following therapy used at optimized dose: Anti H1, Anti H2, Proton pump inhibitor, Osteoclast inhibitor, Cromoglycate Sodium, Antileukotriene~4. Handicapped status defined as at least two of the following handicaps, including at least one among pruritus, flushes, depression and fatigue: pruritus score ≥ 9, number of flushes per week ≥ 8, Hamilton rating scale for depression (HAMD-17) score ≥ 19, number of stools per day ≥ 4, number of mictions per day ≥ 8, Fatigue Impact Scale total score (asthenia) ≥ 75~5. Patients with OPA ≥ 2 (moderate to intolerable general handicap)~6. ECOG ≤ 2~7. Patient with adequate organ function~Exclusion Criteria:~1. Patient with one of the following mastocytosis: Cutaneous Mastocytosis, Not documented Smouldering Systemic Mastocytosis or Indolent Systemic Mastocytosis, Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SM-AHNMD), Mast cell leukemia (MCL), Aggressive systemic mastocytosis (ASM)~2. Previous treatment with any Tyrosine Kinase Inhibitor~3. Patient with recent cardiac history of: Acute coronary syndrome, Acute heart failure, Significant ventricular arrhythmia; patient with cardiac failure class III or IV; Syncope without known aetiology within 3 months, uncontrolled severe hypertension.~4. Patient with any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events Previous treatment~5. Change in the symptomatic treatment of mastocytosis or administration of any new treatment of mastocytosis within 4 weeks prior to baseline~6. Treatment with any investigational agent within 4 weeks prior to baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Masitinib & BSC (Type: EXPERIMENTAL): Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
- Placebo & BSC (Type: PLACEBO_COMPARATOR): Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TEAM: Testosterone Supplementation and Exercise in Elderly Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, untrained men 60 years or older with low-normal testosterone levels (200-350ng/dL)~* Must reside in the Denver metro area~Exclusion Criteria:~* Prostate/breast cancer~* Unable to exercise safely~* severe obesity (\>34 body mass index \[BMI\])~* Polycythemia~* Diabetes~* Use of drugs that could affect T levels~* Cognitive dysfunction (MMSE less than 24)~* PSA above the age-adjusted normal level or AUA greater than 19~* Unable to pass stress test due to active CAD

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LowT+Resistance Training (Type: EXPERIMENTAL): Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~1 year standard Progressive Resistance Training(PRT) program
- LowT+No Resistance training (Type: EXPERIMENTAL): Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~No exercise program
- HighT+Resistance Training (Type: EXPERIMENTAL): High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~1 year standard Progressive Resistance Training(PRT) program
- HighT+No Resistance Training (Type: EXPERIMENTAL): High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~No exercise program
- Placebo+Resistance Training (Type: ACTIVE_COMPARATOR): Placebo Group applies two 2.5 gm placebo packets~1 year standard Progressive Resistance Training(PRT) program
- Placebo+No Resistance Training (Type: PLACEBO_COMPARATOR): Placebo group applies two 2.5 gm placebo packets~No exercise program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have been previously enrolled on TOIT protocol at St. Jude Children's Research Hospital~* Must have original bone marrow donor available and willing to participate as a donor~* Normal liver function~* Hemoglobin \>10gm/dl

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Potential candidate for HCT.~* Histologically confirmed diagnosis by pathologic review of previous diagnosis of high-risk myelodysplastic syndrome (MDS): International Prognostic Scoring System (IPSS) \> 1 or AML-MDS or treatment related MDS.~* Serum bilirubin levels ≤1.5 times the upper limit of the normal (ULN) range for the laboratory. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis; Serum glutamic-oxaloacetic transaminase (SGOT) \[aspartate aminotransferase (AST)\] or serum glutamic pyruvic transaminase (SGPT) \[alanine aminotransferase (ALT)\] levels ≤2 x ULN.~* Serum creatinine levels ≤1.5 x ULN~* Karnofsky performance status greater or equal to 70%~* Signed informed consent form in accordance with institutional policies~Exclusion Criteria:~* Known or suspected hypersensitivity to Vidaza or mannitol~* Pregnant or lactating women~* Human immunodeficiency virus (HIV) or seropositive, confirmed by nucleic acid amplification testing (NAT)~* Active central nervous system (CNS) malignancy~* Active infection~* History or presence of primary hepatoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Combined Therapy (Type: EXPERIMENTAL): 5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with schizophrenia and schizophrenia-related insomnia, no relapse or psychosis for at least 3 months before screening, and considered symptomatically stable~* have apnea/hypopnea score \<10 and periodic leg movement score with an arousal index \<10~* Weigh \>/= 50 kg (\>/=110 lbs), with a BMI \>/= 18 and \</= 35 kg/m2, inclusive~* Agree to adhere to sleep schedule~* Have a sleep history of a minimum of 1.5 hours of wakefulness out of 8 hours in bed.~Exclusion Criteria:~* Current history of suicidal or violent behavior or have exhibited this behavior within the past 6 months~* diagnosis of primary insomnia~* unstable blood pressure~* sleep problems related to general medical conditions, or substance abuse~* diagnosis of or evidence of narcolepsy~* preexisting severe gastrointestinal narrowing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Type 1 diabetes~* Age 18-45 years~* Maximum of 4 years from diagnosis~* Evidence of ≥1 autoantibody against β-cell autoantigens~* Possession of the HLA-DR4 (DRB1\*0401) genotype~* Residual β-cell function (peak C-peptide \>200)~Exclusion Criteria:~* Females who are pregnant, breast-feeding or not using adequate forms of contraception.~* Use of β-cell stimulants, immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to randomization, any monoclonal antibody therapy given for any indication and any antigen-specific

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo injection (Type: PLACEBO_COMPARATOR): Water for injection
- MultiPepT1De injection low dose (Type: EXPERIMENTAL): Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
- MultiPepT1De injection medium dose (Type: EXPERIMENTAL): Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
- MultiPepT1De injection high dose (Type: EXPERIMENTAL): Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete